Clinical Trial Update: A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of HLD-0915 for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma

Drugs mentioned

• HLD-0915

Snippet

Sponsor: Halda Therapeutics OpCo, Inc. | Conditions: Prostate Cancer Metastatic Disease, Prostate Cancer (Adenocarcinoma) | Phase 1, Phase 2 | Status: RECRUITING